Fill Finish Manufacturing Market Size Report | Growth Drivers & Future Outlook 2030

The fill finish manufacturing market size is expected to grow from US$ 8,705.58 million in 2022 and to reach a value of US$ 17,165.41 million by 2030; it is anticipated to record a CAGR of 8.9% from 2022 to 2030.

Market Insights and Analyst View:

Single-use disposable systems (SUDS) and single-use systems (SUS) for aseptic fill finish save time for pharmaceutical manufacturers, thereby allowing them to streamline their operations and shorten project schedules. Incorporating SUDS also helps them ensure regulatory compliance as well as confer environmental, health, and safety (EHS) benefits and facility design advantages. Furthermore, SUS accelerates the changeover fill finish operations by simplifying end-of-batch breakdown and decontamination operations; the simplification of decontamination operations involves the elimination of time-consuming cleaning and preparation steps. The SUS is now being used in fill-finish operations. Bulk biotech operations have successfully deployed single-use systems for buffer and media preparations. They are currently implementing new single-use technologies such as fermentation and chromatography systems. Recent advancements in technology are making SUDS increasingly attractive for aseptic operations. For instance, a single-use line is a perfect fit for parenteral solution products with relatively low batch sizes (50—500L) that a peristaltic pump can transfer. Thus, the rise in the use of single-use systems for aseptic fill finish manufacturing will provide future growth in the fill finish manufacturing market

Growth Drivers and Challenges:

Biologics constitute a majority of the top-selling drugs, and they represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies ~30 years ago, the overall biologics market has grown at an annual rate of more than 12%. Further, over 5,000 biopharmaceutical product candidates are currently under development. Although biopharmaceuticals offer significant profit margins, high development costs and complex production protocols are the key concerns of the sponsors of these pharmacological interventions. As a result, several start-ups and pharmaceutical giants have begun outsourcing different processes of their business operations to contract service providers. Moreover, outsourcing jobs to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) reduces the requirement of capital investments, provides access to larger production capacities, decreases the time-to-market of products, and lowers risks associated with the commercialization of products.

Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Fill finish manufacturing services are currently provided by approximately 180 companies for a variety of biologics. They are located in over 350 fill finish factories for these contract manufacturing companies across various regions.

Furthermore, many service providers have acquired other market players in the recent past to enhance their service offerings. For instance, Sanofi has outsourced the manufacturing of its biologics to Boehringer Ingelheim. In addition, AbbVie's operations have successfully developed and delivered drug products for more than 130 years; over 14 million small-volume parenteral (SVPs) are filled annually across the company’s global network, and the filled products are distributed within ~175 countries. Benefiting from a fully integrated Science and Technology group supporting both biologics drug substance (DS) and drug product (DP) development, AbbVie also has a good audit and regulatory track record with proven clinical and commercial success. With the state-of-the-art aseptic manufacturing line in Ireland, particularly for liquid and lyophilized biologic vials, as well as with the integration of Allergan’s SVP network, AbbVie has further expanded its capability and capacity to more than 40 million units annually. Thus, increasing demand for biologics is driving the market growth.

The role of pharmaceutical outsourcing has changed from being a small part of a business to an integral part of it. The pharmaceutical industry is transforming with the expanding product pipelines, continuous pricing pressure, and emerging markets. Competition in the CMO marketplace has escalated with the growing number of service providers in APAC. Smaller CMOs in the US and Europe are struggling to keep up with the fierce competition, and ultimately, big pharmaceutical companies or other CMOS are acquiring them. For instance, in February 2020, Altasciences, a CMO, acquired Alliance Contract Pharma. This acquisition added small molecule contract manufacturing and analytical services to Altascience's portfolio. Despite ongoing consolidation, the CMO market remains fragmented, with only a few companies achieving global reach and scale.

Moreover, there is a high demand for CMO services offered for niche areas such as antibody-drug conjugation and high-potency drug manufacturing, owing to the significant amounts of investments required to have these capabilities in-house. However, many pharmaceutical companies have started acquiring these facilities to gain a competitive edge over their competitors. This has led to an increase in the prices of these services, making outsourcing a difficult choice for start-ups and small pharmaceutical companies.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Fill Finish Manufacturing Market: Strategic Insights

Market Size Value in	US$ 8,705.58 million in 2022
Market Size Value by	US$ 17,165.41 million by 2030
Growth rate	CAGR of 8.9% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The fill finish manufacturing market is segmented on the basis of product, modality, and end user. Based on product, the fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment is further segmented into prefilled syringes, glass vials/plastic vials, cartridges, and others. By modality, the fill finish manufacturing market is categorized into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. In terms of end users, the fill finish manufacturing market is classified into contract manufacturing organizations, biopharmaceutical companies, and others. Based on geography, the fill finish manufacturing market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, South Korea, Japan, Australia, India, and Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

Based on product, the fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment is further divided into prefilled syringes, glass vials/plastic vials, cartridges, and others. The consumables segment is categorized into cartridges, vials, prefilled syringes, and other consumables such as ampoules, bottles, bags, and single-use systems. The consumables segment holds a significant market share in the fill-finish manufacturing market; it is anticipated to experience a similar growth trend during the forecast period owing to the high replacement rate compared to instruments. Also, consumables' shelf life is less, and they are usually required in large quantities. The rising adoption of prefilled syringes, varied applications of vials in lyophilization, and increasing fill-finish outsourcing are the key factors driving the consumables segment.

Fill Finish Manufacturing Market by Type – 2022 and 2030

Access Data

Based on modality, the fill finish manufacturing market is classified into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. Vaccine fill finish manufacturing is a critical stage in the production process. It involves filling vials with the prepared vaccine and ensuring precise quantities. This step demands stringent quality control to maintain efficacy and safety. Once filled, the vials undergo sealing and packaging. This meticulous process plays a pivotal role in delivering vaccines to the global population, safeguarding public health by meeting quality standards and regulatory requirements. Furthermore, increasing key developments related to vaccine fill finish manufacturing are driving the market growth. For instance, in May 2023, Novocol Pharma—a leading sterile injectable contract development and manufacturing organization (CDMO) in Ontario—and Moderna, Inc.—a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines—announced a long-term agreement to perform aseptic fill finish, labeling, and packaging of mRNA respiratory vaccines expected to be produced in Canada. The last stage of the production cycle, known as fill-finish sterile manufacturing, entails putting the vaccine medication product into vials and preparing it for use. Furthermore, the arrangement with Novocol Pharma will increase the fill finish capacity of vaccines produced at Moderna's mRNA facility in Laval. Subject to planning and regulatory permissions, the facility is anticipated to open for business by the end of 2024

Based on end user, the fill finish manufacturing market is classified into contract manufacturing organizations, biopharmaceutical companies, and others. In 2022, the contract manufacturing organizations segment held the largest share of the market, and it is expected to register the highest CAGR during the forecast period. Contract manufacturing organizations (CMOs) benefit pharmaceutical companies by minimizing investment requirements in facilities and drug development costs, thereby improving the net cash flow. Outsourcing is a cheaper approach that increases the efficiency of manufacturing processes. Also, it allows pharmaceutical and biotechnology companies to redirect resources to other necessary fields. CMO has been considered a niche industry in the past few years, which offered additional manufacturing capacity or specific services to pharmaceutical companies. The rising number of drug manufacturing failures led to a rise in the number of CMOs. Pharmaceutical companies traditionally had dedicated manufacturing facilities for innovative drugs in development. However, to reduce the risk of overcapacities, the demand for manufacturing outsourcing has been rising continuously.

Many pharmaceutical companies have begun refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, resulting in growing reliance on CMOs for manufacturing. Further, the additional capacities in the form of CMOs mitigate the risk of supply shortages. They also offer other sites to pharmaceutical companies for implementing multisite supply strategies and holding backup capacities. For instance, in 2020, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics facilitated GI Innovation with services ranging from f-cell line development to Phase I drug substance production.

Regional Analysis:

Based on geography, the fill finish manufacturing market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of the fill finish manufacturing market. Canada is among the fastest-developing countries in terms of the biopharmaceutical industry. Various international companies are investing in the Canadian biopharmaceutical industry. In Canada, the number of biopharmaceutical companies is rising significantly. For instance, Vancouver, British Columbia, has the majority of biopharmaceutical companies, which generate US$ 90.3 million (CAD 120 million) revenue annually. There are ~35–40 domestic biopharmaceutical companies across the country. A few of the Canadian biopharmaceutical companies include Inex Pharmaceuticals, Quest Vitamins, StressGen Biotechnologies, Stanley Pharmaceuticals, QLT Phototherapeutics, and Stemcell Technologies. Various public and private research organizations include the Center for Molecular Medicine and Therapeutics, the Biotechnology Laboratory at the University of British Columbia, the BC Cancer Research Center, the Canadian HIV Trials Network, and the Vaccine Evaluation Center. Thus, the development of the biopharmaceutical industry in the country will bolster the market growth during the forecast period.

Asia Pacific is expected to be the fastest-growing market in the coming years. In Asia Pacific, China is the largest market for fill finish manufacturing. The growth of the market is primarily attributed to the rising technological advancements in fill finish manufacturing processes in China, increasing developments by the market players, the biopharmaceutical industry’s expansion, and the growing prevalence of chronic diseases. There are more than 500 biological product/biopharmaceutical companies in China. Most of those involved in R&D were established by returnees from abroad or by Western/joint venture companies. Although estimates vary widely, analysts believe that the Chinese government spends more than US$ 600 million annually on biotech R&D through its funding initiatives. China’s national and local governments also invest in quasi-venture capital companies that invest in IT enterprises. The market players are expanding their business through organic and inorganic growth strategies. For instance, WuXi Biologics increased the capacity of prefilled syringes (PFS) to 17 million units yearly in June 2022 by opening its drug product factory in Wuxi, China. The most recent D.P. facility operated by WuXi Bio, a contract development manufacturing organization (CDMO), is called DP5, and it has an advanced isolator filling line for reliable, continuous filling services. According to the company, this provides PFS with a variety of volume delivery options, including 1.25 mL, 3 mL, 1 mL, and 1 mL.

Competitive Landscape and Key Companies:

IMA Industria Macchine Automatiche SpA, Nipro Medical Europe NV, Maquinaria Industrial Dara SL, Groninger and Co GmbH, SGD SA, Optima Packaging Group Gmbh, NNE AS, Stevanato Group SpA, Syntegon Technology GmbH, West Pharmaceutical Services Inc, Gerresheimer AG, Schott AG, and Becton Dickinson and Co are a few prominent players operating in the fill finish manufacturing market. These companies focus on expanding service offerings to meet the growing consumer demand worldwide. Their global presence allows them to serve a large set of customers, subsequently allowing them to expand their market share.